Modality
Cell Therapy
MOA
BCMA ADC
Target
JAK1
Pathway
Checkpoint
Migraine
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
~Aug 2019
→ ~Nov 2020
Phase 3
Feb 2021
→ Jun 2026
Phase 3Current
NCT06710888
1,633 pts·Migraine
2021-02→2026-06·Terminated
1,633 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-132mo awayPh3 Readout· Migraine
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P3
Termina…
Catalysts
Ph3 Readout
2026-06-13 · 2mo away
Migraine
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06710888 | Phase 3 | Migraine | Terminated | 1633 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR |